ProMetic Life Sciences’ (PLI) Outperform Rating Reaffirmed at Scotiabank
ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reissued by equities research analysts at Scotiabank in a research report issued to clients and investors on Tuesday, StockTargetPrices.com reports. They currently have a C$5.00 price target on the stock. Scotiabank’s price objective suggests a potential upside of 110.97% from the stock’s previous close.
Several other research analysts also recently commented on the stock. TD Securities reiterated a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a report on Wednesday, November 23rd. Royal Bank Of Canada restated an “outperform” rating and set a C$4.70 price objective on shares of ProMetic Life Sciences in a report on Tuesday, November 22nd. Canaccord Genuity boosted their price objective on shares of ProMetic Life Sciences from C$4.50 to C$4.75 and gave the stock a “buy” rating in a report on Friday, November 18th. Bloom Burton restated a “hold” rating on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Finally, CIBC dropped their price objective on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) traded up 5.80% during trading on Tuesday, reaching $2.37. 1,436,769 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $2.81 and a 200-day moving average price of $2.90. The company’s market capitalization is $1.47 billion. ProMetic Life Sciences has a 52-week low of $1.88 and a 52-week high of $3.62.
COPYRIGHT VIOLATION NOTICE: “ProMetic Life Sciences’ (PLI) Outperform Rating Reaffirmed at Scotiabank” was originally posted by Financial Market News and is owned by of Financial Market News. If you are accessing this story on another website, it was illegally stolen and reposted in violation of U.S. & international copyright law. The legal version of this story can be viewed at http://www.financial-market-news.com/prometic-life-sciences-pli-outperform-rating-reaffirmed-at-scotiabank/1208596/.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.